Lymphocyte activation gene 3 protein — Drug Target
2 drugs
2 marketed
All drugs that target Lymphocyte activation gene 3 protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Programmed Death Receptor-1 Blocking Antibody [EPC]
Marketed (2)
- Opdualag · Australian & New Zealand Children's Haematology/Oncology Group · Oncology
- OPDUALAG · BRISTOL MYERS SQUIBB · Programmed Death Receptor-1 Blocking Antibody [EPC] · Oncology